Onxeo SA logo

ONXEO - Onxeo SA Share Price

€0.73 -0.0  -4.0%

Last Trade - 4:35pm

Sector
Healthcare
Size
Micro Cap
Market Cap £42.0m
Enterprise Value £44.3m
Revenue £3.88m
Position in Universe 593rd / 853
Bullish
Bearish
Unlock ONXEO Revenue
Momentum
Relative Strength (%)
1m +1.02%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -22.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
22.1 3.48 4.42 9.51 6.13 4.29 17.6 31.3 -27.9%
+240
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2019, Onxeo SA revenues decreased 30% to EUR4.3M. Net loss applicable to common stockholders increased from EUR9.4M to EUR33.7M. Revenues reflect Rest of the World segment decrease of 43% to EUR3.2M, Europe segment decrease of 52% to EUR280K. Higher net loss reflects Share of profit from equity affiliates decrease from EUR5.2M (income) to EUR39K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ONXEO Revenue Unlock ONXEO Revenue

Net Income

ONXEO Net Income Unlock ONXEO Revenue

Normalised EPS

ONXEO Normalised EPS Unlock ONXEO Revenue

PE Ratio Range

ONXEO PE Ratio Range Unlock ONXEO Revenue

Dividend Yield Range

ONXEO Dividend Yield Range Unlock ONXEO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ONXEO EPS Forecasts Unlock ONXEO Revenue
Profile Summary

Onxeo SA, formerly Bioalliance Pharma SA, is a France-based biopharmaceutical company. In July 2014, the Company, as the continuing entity, merged with Topotarget AS creating Onxeo, a company dedicated to orphan oncology diseases. Onxeo aims at holding a portfolio of advanced programs targeting severe pathologies with unmet clinical needs. It has two programs in clinical development stage: Livatag, a doxorubicin Transdrag in Phase III, for the treatment of primary liver cancer, and Validive, a clonidine Lauriad in Phase II, for treatment of radio/chemo-induced severe oral mucositis at patients with head and neck cancer. It also has one registered product in the United States, Beleodaq/ belinostat, for the treatment of peripheral T-Cell lymphoma (PTCL) and opportunities for further development; and two initial drugs registered in Europe and the United States: Loramyc/ Oravig for the treatment of oropharyngeal candidiasis, and Sitavig for the treatment of recurring herpes labialis.

Directors
Last Annual December 31st, 2019
Last Interim December 31st, 2019
Incorporated February 3, 1997
Public Since July 12, 2005
No. of Shareholders: n/a
No. of Employees: 30
Sector Healthcare
Industry Pharmaceuticals
Index CAC Mid & Small , CAC Small , CAC All-tradable , Enternext Pea-pme 150 ,
Exchange Euronext - Paris
Shares in Issue 60,976,782
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ONXEO Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ONXEO
Upcoming Events for ONXEO
Frequently Asked Questions for Onxeo SA
What is the Onxeo SA share price?

As of 4:35pm, shares in Onxeo SA are trading at €0.73, giving the company a market capitalisation of £42.0m. This share price information is delayed by 15 minutes.

How has the Onxeo SA share price performed this year?

Shares in Onxeo SA are currently trading at €0.73 and the price has moved by -4.04% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Onxeo SA price has moved by 3.43% over the past year.

What are the analyst and broker recommendations for Onxeo SA?

Of the analysts with advisory recommendations for Onxeo SA, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Onxeo SA is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Onxeo SA next release its financial results?

Onxeo SA is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2020-12-31
What is the Onxeo SA dividend yield?

Onxeo SA does not currently pay a dividend.

Does Onxeo SA pay a dividend?

Onxeo SA does not currently pay a dividend.

When does Onxeo SA next pay dividends?

Onxeo SA does not currently pay a dividend.

How do I buy Onxeo SA shares?

To buy shares in Onxeo SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Onxeo SA?

Shares in Onxeo SA are currently trading at €0.73, giving the company a market capitalisation of £42.0m.

Where are Onxeo SA shares listed? Where are Onxeo SA shares listed?

Here are the trading details for Onxeo SA:

Country of listing: France
Exchange: PAR
Ticker Symbol: ONXEO
What kind of share is Onxeo SA?

Based on an overall assessment of its quality, value and momentum, Onxeo SA is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Onxeo SA share price forecast 2020?

Shares in Onxeo SA are currently priced at €0.73. At that level they are trading at 46.05% discount to the analyst consensus target price of 0.00.

Analysts covering Onxeo SA currently have a consensus Earnings Per Share (EPS) forecast of 0.125 for the next financial year.

How can I tell whether the Onxeo SA share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Onxeo SA. Over the past six months, the relative strength of its shares against the market has been 58.66%. At the current price of €0.73, shares in Onxeo SA are trading at 36.51% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Onxeo SA PE Ratio?

We were not able to find PE ratio data for Onxeo SA.

Who are the key directors of Onxeo SA?

Onxeo SA's management team is headed by:

Nicolas Fellman - CFO
Remi Droller - DRC
Judith Greciet - CEO
Michel Forest - VPR
Aude Michel - GCN
Nicolas Trebouta - DRC
Louis Kayitalire - VRD
Russell Greig - IND
Daniele Guyot-Caparros - IND
Elisabeth Carstensen - EXB
Audrey Legentil-Dumery - DHR
Joseph Zakrzewski - NEC
Philippe Maitre - EVP
Francoise Bono - CSO
Olivier de Beaumont - EXB
Who are the major shareholders of Onxeo SA?

Here are the top five shareholders of Onxeo SA based on the size of their shareholding:

The Invus Group, LLC Investment Advisor
Percentage owned: 10.72% (8.40m shares)
Besançon & Trébouta Families Individual Investor
Percentage owned: 10.58% (8.29m shares)
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund
Percentage owned: 0.78% (611k shares)
DFA Continental Small Company Series Mutual Fund
Percentage owned: 0.38% (295k shares)
DFA International Core Equity Portfolio Mutual Fund
Percentage owned: 0.26% (204k shares)
Similar to ONXEO
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.